Add to MyPages

This page will be saved to Cincinnati Children's MyPages, a collection of your favorite places. You can view, organize, or delete your favorites at any time.

 (optional)

E-mail this page

(All fields required)


Please enter a valid e-mail.

Please enter your name.

Please enter a valid e-mail.


Share this on:

Biographies

A photo of Yi Zheng.

Yi Zheng, PhD

Director, Division of Experimental Hematology and Cancer Biology; Katherine Stewart Waters Endowed Chair

Co-Director, Cancer and Blood Diseases Institute

Professor, UC Department of Pediatrics

Phone: 513-636-0595

Email: yi.zheng@cchmc.org

Show All

Specialties

Research Interests

Using transgenic and gene targeted mouse models to study the physiological and pathological roles of Rho GTPases and their regulators in hematopoiesis, neurogenesis, lung cancer development and small intestinal stem cell regulations; mechanism based, rational design of small molecule inhibitors targeting Rho GTPase signaling modules and pathologic functions in cancer and blood diseases; mouse model studies of mTor signaling function in hematopoietic stem cells and small intestinal stem cells.

Education and Training

BS: Tsinghua University, Beijing, China, 1986.

MS: Cornell University, Ithaca, NY 1988.

PhD: Cornell University, Ithaca, NY, 1991.

Postdoctoral Fellow: Cornell University, Ithaca, NY, 1995.

Publications

View PubMed Publications

Grants

Rac GTPases as targets in lymphomagenesis. Principal Investigator. National Cancer Institute. Feb 2007 - Jan 2012. #R01 CA125658.

Multi-Photon Confocal Microscope. Principal Investigator. National Institutes of Health. May 2011 - May 2012. #S10RR029406.

Rac GTPases in mammalian brain development. Co-Principal Investigator. National Institute of Neurological Disorder and Stroke. Jul 2008 - Jun 2012. #R01 NS056435.

Training Program in Hematologic and Oncologic Diseases. Principal Investigator. National Institute of Heart, Lung, and Blood. Sep 2008 - Aug 2013. #T32 HL091805.

Rac GTPase specific small molecule inhibitors. Principal Investigator. National Cancer Institute. Jan 2000 - Jan 2014. #R01 CA141341.

Targeting Cdc42 in leukemia stem cells. Co-Principal Investigator. National Cancer Institute. Apr 2010 - Mar 2015. #1R01CA150547-01. 

Cincinnati Center of Excellence in Molecular Hematology. Principal Investigator. National Institutes of Health. Sep 2010 – Jul 2015. # P30 DK090971.

Lineage Determination and Tissue Homeostasis in the aged Hematopoietic System. Contact Principal Investigator / Co-Principal Investigator. National Institutes of Health. Aug 2011 - Aug 2016.